Kura Oncology (KURA) Earning Somewhat Positive News Coverage, Accern Reports
Headlines about Kura Oncology (NASDAQ:KURA) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kura Oncology earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.4406299199538 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Kura Oncology (KURA) opened at 6.95 on Thursday. The stock’s market capitalization is $138.92 million. Kura Oncology has a 12-month low of $4.00 and a 12-month high of $12.10. The stock’s 50 day moving average is $7.99 and its 200 day moving average is $8.70.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. Equities analysts anticipate that Kura Oncology will post ($1.60) EPS for the current fiscal year.
Several research analysts have issued reports on KURA shares. Cann reaffirmed a “buy” rating and issued a $16.00 target price on shares of Kura Oncology in a report on Monday, May 15th. Citigroup Inc. set a $13.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Kura Oncology in a report on Wednesday, June 28th. Zacks Investment Research cut shares of Kura Oncology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 18th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $14.15.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.